Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitior bortezomib

Kai Sun, Lisbeth A. Welniak, Angela Panoskaltsis-Mortari, Matthew J. O'Shaughnessy, Haiyan Liu, Isabel Barao, William Riordan, Raquel Sitcheran, Christian Wysocki, Jonathan S. Serody, Bruce R. Blazar, Thomas J. Sayers, William J. Murphy

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses and promoted the apoptosis of alloreactive T cells. Bortezomib given at the time of allogeneic BMT in mice resulted in significant protection from acute GVHD. Reductions in GVHD-associated parameters and biological evidence of proteasome inhibition were observed with this regimen but with no adverse effects on long-term donor reconstitution. Assessment of graft-versus-tumor responses in advanced leukemia-bearing mice demonstrated that only the combination of allogeneic BMT and T cells with bortezomib promoted significant increases in survival. Increased cytotoxic T cell killing of the tumor was also observed. Thus, the combination of proteasome inhibition with selective immune attack can markedly increase the efficacy of BMT in cancer.

Original languageEnglish (US)
Pages (from-to)8120-8125
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number21
DOIs
StatePublished - May 21 2004

Fingerprint

Graft vs Host Disease
Proteasome Endopeptidase Complex
Bone Marrow Transplantation
Homologous Transplantation
Transplants
T-Lymphocytes
Neoplasms
Proteasome Inhibitors
Bone Marrow Cells
Leukemia
Lymphocytes
Apoptosis
Bortezomib
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitior bortezomib. / Sun, Kai; Welniak, Lisbeth A.; Panoskaltsis-Mortari, Angela; O'Shaughnessy, Matthew J.; Liu, Haiyan; Barao, Isabel; Riordan, William; Sitcheran, Raquel; Wysocki, Christian; Serody, Jonathan S.; Blazar, Bruce R.; Sayers, Thomas J.; Murphy, William J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 21, 21.05.2004, p. 8120-8125.

Research output: Contribution to journalArticle

Sun, K, Welniak, LA, Panoskaltsis-Mortari, A, O'Shaughnessy, MJ, Liu, H, Barao, I, Riordan, W, Sitcheran, R, Wysocki, C, Serody, JS, Blazar, BR, Sayers, TJ & Murphy, WJ 2004, 'Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitior bortezomib', Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 8120-8125. https://doi.org/10.1073/pnas.0401563101
Sun, Kai ; Welniak, Lisbeth A. ; Panoskaltsis-Mortari, Angela ; O'Shaughnessy, Matthew J. ; Liu, Haiyan ; Barao, Isabel ; Riordan, William ; Sitcheran, Raquel ; Wysocki, Christian ; Serody, Jonathan S. ; Blazar, Bruce R. ; Sayers, Thomas J. ; Murphy, William J. / Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitior bortezomib. In: Proceedings of the National Academy of Sciences of the United States of America. 2004 ; Vol. 101, No. 21. pp. 8120-8125.
@article{d6c5d668e77d438daecf97e1a1e0ec9b,
title = "Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitior bortezomib",
abstract = "Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses and promoted the apoptosis of alloreactive T cells. Bortezomib given at the time of allogeneic BMT in mice resulted in significant protection from acute GVHD. Reductions in GVHD-associated parameters and biological evidence of proteasome inhibition were observed with this regimen but with no adverse effects on long-term donor reconstitution. Assessment of graft-versus-tumor responses in advanced leukemia-bearing mice demonstrated that only the combination of allogeneic BMT and T cells with bortezomib promoted significant increases in survival. Increased cytotoxic T cell killing of the tumor was also observed. Thus, the combination of proteasome inhibition with selective immune attack can markedly increase the efficacy of BMT in cancer.",
author = "Kai Sun and Welniak, {Lisbeth A.} and Angela Panoskaltsis-Mortari and O'Shaughnessy, {Matthew J.} and Haiyan Liu and Isabel Barao and William Riordan and Raquel Sitcheran and Christian Wysocki and Serody, {Jonathan S.} and Blazar, {Bruce R.} and Sayers, {Thomas J.} and Murphy, {William J.}",
year = "2004",
month = "5",
day = "21",
doi = "10.1073/pnas.0401563101",
language = "English (US)",
volume = "101",
pages = "8120--8125",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "21",

}

TY - JOUR

T1 - Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitior bortezomib

AU - Sun, Kai

AU - Welniak, Lisbeth A.

AU - Panoskaltsis-Mortari, Angela

AU - O'Shaughnessy, Matthew J.

AU - Liu, Haiyan

AU - Barao, Isabel

AU - Riordan, William

AU - Sitcheran, Raquel

AU - Wysocki, Christian

AU - Serody, Jonathan S.

AU - Blazar, Bruce R.

AU - Sayers, Thomas J.

AU - Murphy, William J.

PY - 2004/5/21

Y1 - 2004/5/21

N2 - Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses and promoted the apoptosis of alloreactive T cells. Bortezomib given at the time of allogeneic BMT in mice resulted in significant protection from acute GVHD. Reductions in GVHD-associated parameters and biological evidence of proteasome inhibition were observed with this regimen but with no adverse effects on long-term donor reconstitution. Assessment of graft-versus-tumor responses in advanced leukemia-bearing mice demonstrated that only the combination of allogeneic BMT and T cells with bortezomib promoted significant increases in survival. Increased cytotoxic T cell killing of the tumor was also observed. Thus, the combination of proteasome inhibition with selective immune attack can markedly increase the efficacy of BMT in cancer.

AB - Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses and promoted the apoptosis of alloreactive T cells. Bortezomib given at the time of allogeneic BMT in mice resulted in significant protection from acute GVHD. Reductions in GVHD-associated parameters and biological evidence of proteasome inhibition were observed with this regimen but with no adverse effects on long-term donor reconstitution. Assessment of graft-versus-tumor responses in advanced leukemia-bearing mice demonstrated that only the combination of allogeneic BMT and T cells with bortezomib promoted significant increases in survival. Increased cytotoxic T cell killing of the tumor was also observed. Thus, the combination of proteasome inhibition with selective immune attack can markedly increase the efficacy of BMT in cancer.

UR - http://www.scopus.com/inward/record.url?scp=2542599273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542599273&partnerID=8YFLogxK

U2 - 10.1073/pnas.0401563101

DO - 10.1073/pnas.0401563101

M3 - Article

C2 - 15148407

AN - SCOPUS:2542599273

VL - 101

SP - 8120

EP - 8125

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 21

ER -